News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Liz Santarsiero

Articles by Liz Santarsiero

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

ByRadhika Appaya,Sarah Sammons, MD,Priyanka Sharma, MD,Yara Abdou,VK Gadi, MD, PhD,Taavy A. Miller,Spencer S. Langerman,Dominick Latremouille-Viau,Annie Guerin,Carmine Rossi,Emily McGovern,Gary Sopher,Vamsi Bollu,Natalia Bolotova,Şerban R. Iorga,Liz Santarsiero,Susan Dent, MD

June 30th 2025

26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database

ByPaolo Tarantino, MD, PhD,Hope S. Rugo, MD,Guiseppe Curigliano,Joyce O’Shaughnessy, MD,Wolfgang Janni,Komal Jhaveri,Jason Mouabbi,Adam M. Brufsky, MD, PhD,Erika P. Hamilton, MD,Ruth M. O’Regan, Julia Kim,Liz Santarsiero,Murat Akdere,Fen Ye,Henry Owusu,Stephanie L. Graff, MD

June 20th 2025

24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study

24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study

ByErica L. Mayer, MD, MPH,Mary Lou Smith,Annie Guérin,Dominick Latrémouille-Viau,Nisha C. Hazra,Yan Meng,Wendi Qu,Remi Bellefleur,Vaidyanathan Ganapathy,Liz Santarsiero,Robert Morlock,Maryam Lustberg

August 2nd 2024

50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials

ByDenise A. Yardley, MD,Yoon Sim Yap,Hamdy Abdel Azim,Richard De Boer,Mario Campone,Alistair Ring,Michelino De Laurentiis,Joyce A. O’Shaughnessy,Javier Cortes,Yogesh Chattar,Astrid Thuerigen,Juan Pablo Zarate,Liz Santarsiero

April 27th 2023

Latest Updated Articles

26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database
Published: June 20th 2025 | Updated:

Trending on CancerNetwork

FDA Accepts Topical Gel sNDA for Superficial Basal Cell Carcinoma

Bridging the "Survivorship Cliff" After Radiotherapy for Breast Cancer

How Can a Novel Small Molecule Manage a Unique Multiple Myeloma Subtype?

Joining Commercialization and Innovation to Bring New Cancer Therapies

Remote Exercise Program for Patients With Metastatic Renal Cell Carcinoma Undergoing Immunotherapy: An EXIO Case Series Report